ClinicalTrials.gg
CompletedNCT01649635PROSPECTAUpdated Jul 6, 2016

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

A Phase 4 interventional study of CABAZITAXEL (XRP6258) and Prednisone in Prostate Cancer, sponsored by Sanofi. Completed at 6 sites in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-06.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
27th of 46
45 · median 60
Started
2012
with 5 others
Phase 4
2 of 46
none open now
Registered
12th of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 27th largest by enrollment, is one of 6 that started in 2012, is one of 2 in phase 4, and was the 12th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.

Secondary Objectives:

  • PSA response rate;
  • Descriptive assessment of CTC (circulating Tumor Cells);
  • Rates of grade ≥ 3 neutropenia and febrile neutropenia and grade ≥3 diarrhea over the treatment period;
  • Description of the Health Quality of Life of the patients;
  • Incidence of adverse events.
Read the detailed description

Screening: 15 days Treatment: until disease progression Post-treatment Follow-up: 12 months

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven Castration-Resistant Prostate Cancer (stage IV only);
  • Prior failure of treatment with docetaxel; o Documentation of by imaging.
  • Performance status 0 or 1;

Exclusion criteria

Exclusion criteria:

  • Previous treatment with chemotherapy, except for docetaxel;
  • Previous use of abiraterone;
  • Inability to maintain treatment with androgen deprivation if no previous history of orchiectomy;
  • Presence of any other active or history of any tumor diagnosed in the last 5 years, except basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the skin, bladder or anal canal (these tumors do not prevent participation if they have been treated, even in the last 5 years);
  • or known allergy to any of the treatments under study, including history of severe hypersensitivity reaction (≥grade 3) to docetaxel and/or to polysorbate 80 containing drugs
  • History of congestive heart failure or myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmias, angina pectoris or uncontrolled hypertension;
  • Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
  • Presence of severe comorbidity, which in the opinion of the investigator, puts the patient at risk or impairs compliance to the protocol;
  • Known seropositivity for ;
  • Presence of significant psychiatric or neurological disease, in the investigator's opinion;
  • Presence of uncontrolled hypercalcemia;
  • Refusal to use appropriate during the study period;
  • Participation in any clinical trial in the last 12 months, unless there is benefit to the patient to be justified by the principal investigator
  • Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5
  • Inadequate organ and bone marrow function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3

    Drug: CABAZITAXEL (XRP6258) · Drug: Prednisone · Drug: Ciprofloxacin · Drug: G-CSF (Granulocyte colony-stimulating factor)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with some episode of neutropenia classified as grade ≥ 3

    Time frame: 21 days

Secondary outcomes

  1. Proportion of patients with episode of neutropenia grade ≥3

    Time frame: up to 24 months (every 21 days)

  2. Rate of febrile neutropenia

    Time frame: up to 24 months (every 21 days)

  3. Rate of diarrhea grade ≥3

    Time frame: up to 24 months (every 21 days)

  4. PSA response rate

    Time frame: up to 24 months (every 21 days)

  5. Circulating Tumor Cells Count (CTC) rate

    Time frame: Day 42, Day 84, Day 126 and End of Treatment

  6. Changes from baseline in score derived from the Functional assessment of cancer therapy-prostate (FACT-P) and the Trial Outcome Index (TOI)

    Time frame: up to 24 months (every 21 days)

  7. Number of patients with adverse events

    Time frame: up to 24 months (every 21 days)

07

Study locations

6 sites
  • Investigational Site Number 007
    Centro, 78020-400, Brazil
  • Investigational Site Number 004
    Curitiba, 81520-060, Brazil
  • Investigational Site Number 006
    Lajeado, 95900-000, Brazil
  • Investigational Site Number 005
    Porto Alegre, 90035-903, Brazil
  • Investigational Site Number 001
    Santo Andre, 09050-360, Brazil
  • Investigational Site Number 002
    São Paulo, 01321-001, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jan 2014 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2012
First posted
Jul 25, 2012
Start
Jul 2012
Primary completionActual
Jan 2014
CompletionActual
Jun 2016
Last update
Jul 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01649635
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Jul 2012
Primary completion
Jan 2014
Completion
Jun 2016
Last update
Jul 6, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabazitaxel · Prednisone

Start the discussion